CDK2

Across TCGA pan-cancer cohorts, CDK2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CDK2 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CDK2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDK2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where CDK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.236	0.582	.001	58	view →
COAD	DFS	Median	II,III,IV	0.906	1.000	.007	48	view →
CCRCC	OS	Quartile	II,III,IV	0.530	0.852	.014	20	view →
HNSC	OS	Quartile	All	0.121	1.000	.017	15	view →
UCEC	DFS	Tertile	All	0.803	1.000	.002	12	view →
LUAD	DFS	Tertile	III,IV	0.747	0.391	.031	4	view →
LSCC	DFS	Median	All	0.971	0.909	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CDK2–PDAC (DFS)

Open the PDAC breakdown →